AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Signal recognition particle subunit SRP54 including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Signal recognition particle subunit SRP54 therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Signal recognition particle subunit SRP54, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Signal recognition particle subunit SRP54. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Signal recognition particle subunit SRP54. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Signal recognition particle subunit SRP54 includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Signal recognition particle subunit SRP54
partner:
Reaxense
upacc:
P61011
UPID:
SRP54_HUMAN
Alternative names:
Signal recognition particle 54 kDa protein
Alternative UPACC:
P61011; B2R759; B4DUW6; P13624
Background:
The Signal recognition particle subunit SRP54, a 54 kDa protein, plays a pivotal role in the cotranslational targeting of secretory and membrane proteins to the endoplasmic reticulum (ER). It is a key component of the signal recognition particle (SRP) complex, facilitating the interaction with the SRP receptor and the subsequent translocation of proteins into the ER. SRP54's GTPase activity is crucial for this process, enabling the dynamic rearrangement necessary for efficient protein targeting.
Therapeutic significance:
SRP54's involvement in severe congenital neutropenia underscores its therapeutic potential. By understanding its role in granulocytic cell proliferation, neutrophil migration, and exocrine pancreas development, novel strategies for treating this hematopoiesis disorder could be developed, offering hope for patients suffering from this condition.
